CN115040641B - Preoperative intervention pharmaceutical composition for neurosurgery - Google Patents

Abstract

The present invention relates to the field of neuropharmaceutical technology, and in particular to a preoperative neurosurgery intervention drug composition, comprising 60% to 80% of component A, including the following ingredients: botulinum neurotoxin, non-protein stabilizer, ophiopogon japonicus polysaccharide, pH buffer and pure water; 20% to 40% of component B, including the following ingredients: saffron, luffa, trachelospermum officinale, cysteine, dextrose and sodium pyrophosphate. In the preparation process, the present invention uses ophiopogon japonicus polysaccharide to ensure the production and preparation environment while improving the stability of the mixture, so that the application effect of the final composition is better, and sodium pyrophosphate is further added after extraction, and concentrated and dried to obtain a pharmaceutical composition, the main body of the drug is high in quality, so that the composition can better improve the nerve conduction velocity after application.

Description

Neurosurgery preoperative intervention drug composition

Technical Field

The present invention relates to the technical field of neurological drugs, and in particular to a preoperative intervention drug composition for neurosurgery.

Background Art

Neurosurgery, also often called brain surgery, is a branch of surgery that uses surgical methods to diagnose and treat diseases of the central nervous system, peripheral nervous system, and autonomic nervous system and their supporting structures (skull, spine, etc.). Neurosurgery is recognized as the highest-ranking field in medicine because of the extremely complex knowledge base required of doctors to perform such operations and the strict screening required to obtain permission to perform such operations. Before being allowed to perform neurosurgery, a doctor needs to undergo at least six to seven years of training, which is also the longest and most demanding of all medical specialties.

Drug pretreatment is required before neurosurgery, but existing neurological drugs have not shown significant improvement in nerve conduction velocity (NCV) after use.

Therefore, we propose a neurosurgery preoperative intervention pharmaceutical composition to solve the above problems.

Summary of the invention

The purpose of the present invention is to solve the shortcomings of the prior art and to propose a neurosurgery preoperative intervention drug composition.

In order to achieve the above object, the present invention adopts the following technical solutions:

The neurosurgery preoperative intervention drug composition proposed by the present invention comprises: 60% to 80% of component A, which comprises the following ingredients in parts by weight: 100 to 200 parts of botulinum neurotoxin, 10 to 30 parts of non-protein stabilizer, 10 to 15 parts of ophiopogon polysaccharide, 3 to 8 parts of pH buffer and 150 to 300 parts of pure water; 20% to 40% of component B, which comprises the following ingredients in parts by weight: 30 to 80 parts of saffron, 20 to 50 parts of luffa, 20 to 70 parts of trachelospermum officinale, 25 to 40 parts of cysteine, 10 to 20 parts of dextrose and 15 to 30 parts of sodium pyrophosphate.

Preferably, the pharmaceutical composition for preoperative intervention in neurosurgery comprises 70% of component A and 30% of component B.

Preferably, the component A comprises the following ingredients in parts by weight: 150 parts of botulinum neurotoxin, 20 parts of non-protein stabilizer, 13 parts of Ophiopogon japonicus polysaccharide, 5 parts of pH buffer and 220 parts of pure water, and the component B comprises the following ingredients in parts by weight: 40 parts of saffron, 35 parts of Luffa fructus, 45 parts of Trachelospermum jasminoides, 35 parts of cysteine, 15 parts of dextrose and 20 parts of sodium pyrophosphate.

Preferably, the component A further comprises 10 to 15 parts by weight of antifreeze.

Preferably, the antifreeze agent is one or more of inositol, mannitol and sorbitol.

Preferably, the non-proteinaceous stabilizer is hyaluronic acid, and the pH buffer is sodium acetate.

Another aspect of the present invention provides a method for preparing a neurosurgery preoperative intervention pharmaceutical composition, comprising the following steps:

S1: Add botulinum neurotoxin to pure water, add non-protein stabilizer at the same time, continue stirring, add pH buffer during stirring, let stand for 10-15 minutes after stirring, then adjust the temperature to 30-35°C, add Ophiopogon japonicus polysaccharide, continue stirring for 10-15 minutes until uniform, and obtain a mixture;

S2: Add antifreeze to the mixture and continue stirring for 10 to 15 minutes;

S3: grinding saffron, luffa and trachelospermum officinale, and then adding cysteine and dextrose to perform warm immersion extraction to obtain medicinal residues and extract;

S4: adding sodium pyrophosphate to the extract, stirring continuously for 10 to 20 minutes, and then performing reflux extraction, and after completion, concentrating and drying to obtain a dry product;

S5: Mix the dried product with the mixed product in S1 to obtain an intervention drug composition.

Preferably, in S1, a pH buffer is added during the stirring process, and after the stirring is completed, the mixture is allowed to stand for 12 minutes, and then the temperature is adjusted to 32° C., Ophiopogon japonicus polysaccharide is added, and stirring is continued for 12 minutes until the mixture is uniform to obtain a mixture.

Preferably, in S3, the warm immersion extraction is performed 2 to 4 times, and each extraction time is 120 to 180 minutes.

Another aspect of the present invention provides a use of a pre-neurosurgical intervention pharmaceutical composition, including the above-mentioned intervention pharmaceutical composition.

Compared with the prior art, the present invention has the following beneficial effects:

1. The present invention divides the composition into two parts for processing, one of which involves botulinum neurotoxin and a non-protein stabilizer (hyaluronic acid), and a pH buffer is used in the process. Further, Ophiopogon japonicus polysaccharide is used in the preparation process to ensure the production and preparation environment while improving the stability of the mixture, so that the application effect of the final composition is better.

2. The present invention arranges saffron, loofah and trachelospermum officinale in another part, grinds them, and then mixes and extracts them with cysteine and dextrose. After the extraction, sodium pyrophosphate is further added, and the mixture is concentrated and dried to obtain a pharmaceutical composition. The main body of the drug has high quality, so that the composition can better improve the nerve conduction velocity after application.

DETAILED DESCRIPTION

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. In the event of a conflict, the definitions in the specification shall prevail. "When mass, concentration, temperature, time, or other value or parameter is expressed as a range, a preferred range, or a range defined by a series of upper preferred values and lower preferred values, this should be understood to specifically disclose all ranges formed by any pairing of any upper range limit or preferred value with any lower range limit or preferred value, regardless of whether the range is disclosed separately. For example, a range of 1-50 should be understood to include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 6, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, any number, combination of numbers, or subrange, and all decimal values between the above integers, for example, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, and 1.9. With respect to subranges, "nested subranges" extending from any endpoint within the range are specifically contemplated. For example, nested subranges of the exemplary range 1-50 may include 1-10, 1-20, 1-30, and 1-40 in one direction, or 50-40, 50-30, 50-20, and 50-10 in the other direction."

The present invention is further explained below in conjunction with specific examples. In the following examples, various processes and methods not described in detail are conventional methods known in the art. The materials, reagents, devices, instruments, equipment, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.

Embodiment 1

A neurosurgery preoperative intervention drug composition comprising:

70% of component A, comprising the following ingredients by weight: 100 parts of botulinum neurotoxin, 10 parts of non-protein stabilizer, 10 parts of ophiopogon polysaccharide, 3 parts of pH buffer, 150 parts of pure water, and 10 parts of antifreeze;

30% of component B comprises the following ingredients by weight: 30 parts of saffron, 20 parts of luffa, 20 parts of trachelospermum officinale, 25 parts of cysteine, 10 parts of dextrose and 15 parts of sodium pyrophosphate.

The antifreeze agent is one or more of inositol, mannitol and sorbitol, the non-protein stabilizer is hyaluronic acid, and the pH buffer is sodium acetate.

In the embodiment, a method for preparing a neurosurgery preoperative intervention pharmaceutical composition is also proposed, comprising the following steps:

S1: Add botulinum neurotoxin to pure water, add non-protein stabilizer at the same time, continue stirring, add pH buffer during stirring, let stand for 10 minutes after stirring, then adjust the temperature to 30°C, add Ophiopogon japonicus polysaccharide, continue stirring for 10 minutes until uniform, and obtain a mixture;

S2: Add antifreeze to the mixture and continue stirring for 10 minutes;

S3: Grind saffron, luffa and Trachelospermum officinale, then add cysteine and dextrose, perform warm immersion extraction, extract twice, each extraction time is 120 minutes, and obtain medicinal residues and extract;

S4: adding sodium pyrophosphate to the extract, stirring continuously for 10 minutes, and then performing reflux extraction, and after completion, concentrating and drying to obtain a dry product;

S5: Mix the dried product with the mixed product in S1 to obtain an intervention drug composition.

Embodiment 2

A neurosurgery preoperative intervention drug composition comprising:

70% of component A, comprising the following ingredients by weight: 120 parts of botulinum neurotoxin, 15 parts of non-protein stabilizer, 12 parts of ophiopogon polysaccharide, 4 parts of pH buffer, 180 parts of pure water, and 12 parts of antifreeze;

30% of component B comprises the following ingredients by weight: 40 parts of saffron, 30 parts of luffa, 35 parts of trachelospermum officinale, 30 parts of cysteine, 14 parts of dextrose and 18 parts of sodium pyrophosphate.

The antifreeze agent is one or more of inositol, mannitol and sorbitol, the non-protein stabilizer is hyaluronic acid, and the pH buffer is sodium acetate.

In the embodiment, a method for preparing a neurosurgery preoperative intervention pharmaceutical composition is also proposed, comprising the following steps:

S1: Add botulinum neurotoxin to pure water, add non-protein stabilizer at the same time, continue stirring, add pH buffer during stirring, let stand for 12 minutes after stirring, then adjust the temperature to 32°C, add Ophiopogon japonicus polysaccharide, continue stirring for 12 minutes until uniform, and obtain a mixture;

S2: Add antifreeze to the mixture and continue stirring for 12 minutes;

S3: Grind saffron, luffa and Trachelospermum officinale, then add cysteine and dextrose, perform warm immersion extraction, extract for 3 times, each extraction time is 150 minutes, and obtain medicinal residues and extract;

S4: adding sodium pyrophosphate to the extract, stirring continuously for 14 minutes, and then performing reflux extraction, and after completion, concentrating and drying to obtain a dry product;

S5: Mix the dried product with the mixed product in S1 to obtain an intervention drug composition.

Embodiment 3

A neurosurgery preoperative intervention drug composition comprising:

70% of component A, comprising the following ingredients by weight: 180 parts of botulinum neurotoxin, 25 parts of non-protein stabilizer, 14 parts of ophiopogon polysaccharide, 7 parts of pH buffer, 250 parts of pure water, and 14 parts of antifreeze;

30% of component B comprises the following ingredients by weight: 70 parts of saffron, 45 parts of luffa, 65 parts of trachelospermum officinale, 35 parts of cysteine, 18 parts of dextrose and 25 parts of sodium pyrophosphate.

The antifreeze agent is one or more of inositol, mannitol and sorbitol, the non-protein stabilizer is hyaluronic acid, and the pH buffer is sodium acetate.

In the embodiment, a method for preparing a neurosurgery preoperative intervention pharmaceutical composition is also proposed, comprising the following steps:

S1: Add botulinum neurotoxin to pure water, add non-protein stabilizer at the same time, continue stirring, add pH buffer during stirring, let stand for 14 minutes after stirring, then adjust the temperature to 34°C, add Ophiopogon japonicus polysaccharide, continue stirring for 14 minutes until uniform, and obtain a mixture;

S2: Add antifreeze to the mixture and continue stirring for 14 minutes;

S3: Grind saffron, luffa and Trachelospermum officinale, then add cysteine and dextrose, perform warm immersion extraction, extract 3 times, each extraction time is 160 minutes, and obtain medicinal residues and extract;

S4: adding sodium pyrophosphate to the extract, stirring continuously for 18 minutes, and then performing reflux extraction, and after completion, concentrating and drying to obtain a dry product;

S5: Mix the dried product with the mixed product in S1 to obtain an intervention drug composition.

Embodiment 4

A neurosurgery preoperative intervention drug composition comprising:

70% of component A, comprising the following ingredients by weight: 200 parts of botulinum neurotoxin, 30 parts of non-protein stabilizer, 15 parts of ophiopogon polysaccharide, 8 parts of pH buffer, 300 parts of pure water, and 15 parts of antifreeze;

30% of component B comprises the following ingredients by weight: 80 parts of saffron, 50 parts of luffa, 70 parts of trachelospermum officinale, 40 parts of cysteine, 20 parts of dextrose and 30 parts of sodium pyrophosphate.

The antifreeze agent is one or more of inositol, mannitol and sorbitol, the non-protein stabilizer is hyaluronic acid, and the pH buffer is sodium acetate.

In the embodiment, a method for preparing a neurosurgery preoperative intervention pharmaceutical composition is also proposed, comprising the following steps:

S1: Add botulinum neurotoxin to pure water, add non-protein stabilizer at the same time, continue stirring, add pH buffer during stirring, let stand for 15 minutes after stirring, then adjust the temperature to 35°C, add Ophiopogon japonicus polysaccharide, continue stirring for 15 minutes until uniform, and obtain a mixture;

S2: Add antifreeze to the mixture and continue stirring for 15 minutes;

S3: Grind saffron, luffa and Trachelospermum officinale, then add cysteine and dextrose, perform warm immersion extraction, extract 4 times, each extraction time is 180 minutes, and obtain medicinal residues and extract;

S4: adding sodium pyrophosphate to the extract, stirring continuously for 20 minutes, and then performing reflux extraction, and after completion, concentrating and drying to obtain a dry product;

S5: Mix the dried product with the mixed product in S1 to obtain an intervention drug composition.

Comparative Example 1

A neurosurgery preoperative intervention drug composition comprising:

70% of component A, comprising the following ingredients by weight: 200 parts of botulinum neurotoxin, 30 parts of non-proteinaceous stabilizer, 8 parts of pH buffer, 300 parts of pure water, and 15 parts of antifreeze;

30% of component B comprises the following ingredients by weight: 80 parts of saffron, 50 parts of luffa, 70 parts of trachelospermum officinale, 40 parts of cysteine, 20 parts of dextrose and 30 parts of sodium pyrophosphate.

The antifreeze agent is one or more of inositol, mannitol and sorbitol, the non-protein stabilizer is hyaluronic acid, and the pH buffer is sodium acetate.

In the comparative example, a method for preparing a neurosurgery preoperative intervention drug composition is also proposed, comprising the following steps:

S1: Add botulinum neurotoxin to pure water and a non-protein stabilizer, and continue stirring. Add a pH buffer during the stirring process, and let stand for 15 minutes after the stirring is completed to obtain a mixture;

S2: Add antifreeze to the mixture and continue stirring for 15 minutes;

S3: Grind saffron, luffa and Trachelospermum officinale, then add cysteine and dextrose, perform warm immersion extraction, extract 4 times, each extraction time is 180 minutes, and obtain medicinal residues and extract;

S4: adding sodium pyrophosphate to the extract, stirring continuously for 20 minutes, and then performing reflux extraction, and after completion, concentrating and drying to obtain a dry product;

S5: Mix the dried product with the mixed product in S1 to obtain an intervention drug composition.

Comparative Example 2

A neurosurgery preoperative intervention drug composition comprising:

70% of component A, comprising the following ingredients by weight: 200 parts of botulinum neurotoxin, 30 parts of non-protein stabilizer, 15 parts of ophiopogon polysaccharide, 8 parts of pH buffer, 300 parts of pure water, and 15 parts of antifreeze;

30% of component B comprises the following ingredients by weight: 80 parts of saffron, 50 parts of luffa, 70 parts of trachelospermum officinale, 40 parts of cysteine and 20 parts of dextrose.

The antifreeze agent is one or more of inositol, mannitol and sorbitol, the non-protein stabilizer is hyaluronic acid, and the pH buffer is sodium acetate.

In the comparative example, a method for preparing a neurosurgery preoperative intervention drug composition is also proposed, comprising the following steps:

S1: Add botulinum neurotoxin to pure water, add non-protein stabilizer at the same time, continue stirring, add pH buffer during stirring, let stand for 15 minutes after stirring, then adjust the temperature to 35°C, add Ophiopogon japonicus polysaccharide, continue stirring for 15 minutes until uniform, and obtain a mixture;

S2: Add antifreeze to the mixture and continue stirring for 15 minutes;

S3: Grind saffron, luffa and Trachelospermum officinale, then add cysteine and dextrose, perform warm immersion extraction, extract 4 times, each extraction time is 180 minutes, and obtain medicinal residues and extract;

S4: Mix the extract and the mixture in S1 to obtain an intervention drug composition.

Comparative Example 3

A neurosurgery preoperative intervention drug composition comprising:

70% of component A, comprising the following ingredients by weight: 200 parts of botulinum neurotoxin, 30 parts of non-proteinaceous stabilizer, 8 parts of pH buffer, 300 parts of pure water, and 15 parts of antifreeze;

30% of component B comprises the following ingredients by weight: 80 parts of saffron, 50 parts of luffa, 70 parts of trachelospermum officinale, 40 parts of cysteine and 20 parts of dextrose.

The antifreeze agent is one or more of inositol, mannitol and sorbitol, the non-protein stabilizer is hyaluronic acid, and the pH buffer is sodium acetate.

In the comparative example, a method for preparing a neurosurgery preoperative intervention drug composition is also proposed, comprising the following steps:

S1: Add botulinum neurotoxin to pure water and a non-protein stabilizer, and continue stirring. Add a pH buffer during the stirring process, and let stand for 15 minutes after the stirring is completed to obtain a mixture;

S2: Add antifreeze to the mixture and continue stirring for 15 minutes;

S3: Grind saffron, luffa and Trachelospermum officinale, then add cysteine and dextrose, perform warm immersion extraction, extract 4 times, each extraction time is 180 minutes, and obtain medicinal residues and extract;

S4: Mix the extract and the mixture in S1 to obtain an intervention drug composition.

The pharmaceutical compositions prepared in the above-mentioned Examples 1 to 4 and Comparative Examples 1 to 3 were tested (2 ml was administered daily), and the results are shown in Table 1:

Table 1

NCV (D/L) Hematocrit (%) Embodiment 1 62.914 46.72 Embodiment 2 63.127 47.31 Embodiment 3 63.195 47.78 Embodiment 4 63.273 47.63 Comparative Example 1 47.864 43.91 Comparative Example 2 61.296 24.84 Comparative Example 3 46.461 22.65

Among them, male rats weighing 250-300g and about 10 weeks old were used in the detection process. STZ solution was freshly prepared into 2% solution with 0.1mol/L sterile citric acid-sodium citrate buffer solution using 0.1mol/L citric acid buffer (pH=4.4). The rats were fasted for 10h and injected into the tail vein at 45mg/kg. Fasting blood glucose (FBG) was measured 7 days after administration. Those with fasting blood glucose above 15mmol/L were DPN rats. Under ketamine hydrochloride (100mg/kg) anesthesia, two acupuncture needles were inserted into the upper and lower sides of the femoral neck as stimulation electrodes at the upper end of the sciatic nerve. The irrelevant electrode was placed on the rat's buttocks. The stimulation parameters of the IL-B electrical stimulator were: square wave pulse, super-strong stimulation, and frequency 1HZ. A concentric circle electrode was inserted into the gastrocnemius muscle belly 1 cm inward and upward above the lateral malleolus of the rat, and the gastrocnemius action potential induced by electrical stimulation was recorded. The waveform was observed with a SR46 two-wire oscilloscope, and the instrument was debugged. After the waveform was stable, the signal was input into the microcomputer, and the AVERAGE level in the SMUP electrophysiological analysis software system developed by the Department of Physiology of Shanghai Medical University was used to record, measure, and print. The NCV was obtained based on the difference in the M wave latency (L) of the gastrocnemius action potential induced by stimulating the two points of the sciatic nerve and the distance (D) between the two stimulation points.

From the above Table 1, it can be clearly seen that in Examples 1 to 4, the NCV of rats is relatively high, and the hematocrit is about 45%. After use, the pharmaceutical composition can better increase the nerve conduction velocity and improve the hematocrit.

In Example 4 and Comparative Example 1, where other conditions were the same, the Ophiopogon japonicus polysaccharide was not used in Comparative Example 1, so that after use of the final composition, the improvement in nerve conduction velocity was reduced, while the hematocrit did not change significantly;

In the comparison between Comparative Example 2 and Example 4, in the treatment of the second component in Comparative Example 2, sodium pyrophosphate was not added, so that the hematocrit of the final composition was reduced after use, while the nerve conduction velocity did not change much;

In comparative example 3, the supporting treatment of Ophiopogon japonicus polysaccharide was not carried out, and in the treatment of the second component, sodium pyrophosphate was not added. After use of the final composition, the improvement of nerve conduction velocity was reduced and the hematocrit was reduced.

In summary, the present invention divides the composition into two parts for processing, one of which involves botulinum neurotoxin and a non-protein stabilizer (hyaluronic acid), and a pH buffer is used in the process. Further, Ophiopogon japonicus polysaccharide is used in the preparation process to ensure the production and preparation environment while improving the stability of the mixture, so that the application effect of the final composition is better.

In another part, saffron, loofah and trachelospermum officinale are arranged, and they are ground, and then mixed with cysteine and dextrose and extracted. After the extraction, sodium pyrophosphate is further added, and the mixture is concentrated and dried to obtain a pharmaceutical composition. The main body of the drug has high quality, so that the composition can better improve the nerve conduction velocity after application.

The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims (10)

1. A pharmaceutical composition for neurosurgical preoperative intervention, the raw materials comprising:

60-80% of A component comprises the following components in parts by weight: 100-200 parts of botulinum neurotoxin, 10-30 parts of non-protein stabilizer, 10-15 parts of ophiopogon polysaccharide, 3-8 parts of pH buffering agent and 150-300 parts of pure water;

20-40% of a component B, which comprises the following components in parts by weight: 30-80 parts of saffron, 20-50 parts of loofah sponge, 20-70 parts of Chinese starjasmine stem, 25-40 parts of cysteine, 10-20 parts of dextrose and 15-30 parts of sodium pyrophosphate;

the non-proteinaceous stabilizing agent is hyaluronic acid.

2. The pre-neurosurgical intervention pharmaceutical composition according to claim 1 comprising 70% of the a component and 30% of the B component.

3. The neurosurgical preoperative intervention pharmaceutical composition according to claim 1, wherein the a component comprises the following components in parts by weight: 150 parts of botulinum neurotoxin, 20 parts of non-protein stabilizer, 13 parts of ophiopogon polysaccharide, 5 parts of pH buffer and 220 parts of pure water, wherein the component B comprises the following components in parts by weight: 40 parts of saffron, 35 parts of loofah, 45 parts of Chinese starjasmine stem, 35 parts of cysteine, 15 parts of dextrose and 20 parts of sodium pyrophosphate.

4. The neurosurgical preoperative intervention pharmaceutical composition according to claim 1, wherein the a component further comprises 10-15 parts by weight of an antifreezing agent.

5. The pre-neurosurgical intervention pharmaceutical composition according to claim 4, wherein the cryoprotectant is one or more of inositol, mannitol and sorbitol.

6. The pre-neurosurgical intervention pharmaceutical composition according to any of the claims 1-5, wherein the pH buffering agent is sodium acetate.

7. A method of preparing a neurosurgical preoperative intervention pharmaceutical composition according to any of claims 1 to 6, comprising the steps of:

s1: adding botulinum neurotoxin into pure water, adding a non-protein stabilizer, continuously stirring, adding a pH buffering agent in the stirring process, standing for 10-15 min after stirring, adjusting the temperature to 30-35 ℃, adding ophiopogon polysaccharide, and continuously stirring for 10-15 min to be uniform to obtain a uniformly mixed substance;

S2: adding an antifreezing agent into the uniformly mixed matter, and continuously stirring for 10-15 min;

s3: grinding stigma croci, retinervus Luffae fructus, and caulis Trachelospermi, adding cysteine and dextrose, and performing warm leaching to obtain residue and extractive solution;

s4: adding sodium pyrophosphate into the extracting solution, continuously stirring for 10-20 min, then carrying out reflux extraction, concentrating and drying after the reflux extraction is completed to obtain a dried product;

S5: and (3) uniformly mixing the dried substance with the uniformly mixed substance in the S1 to obtain the intervention pharmaceutical composition.

8. The method for preparing a pharmaceutical composition for preneurosurgical intervention according to claim 7, wherein in S1, a pH buffer is added during stirring, the mixture is left to stand for 12min after stirring, the temperature is adjusted to 32 ℃, and ophiopogon japonicus polysaccharide is added, and stirring is continued for 12min until uniformity is achieved, so as to obtain a mixture.

9. The method for preparing a pre-neurosurgical intervention pharmaceutical composition according to claim 7, wherein in S3, the extraction is performed 2-4 times with each extraction time being 120-180 min.

10. Use of a pharmaceutical composition for the preparation of a neurosurgical preoperative intervention drug, characterized in that it comprises an intervention pharmaceutical composition according to any of claims 1-9.